Year: 2021

Press Release  November 4, 2021 Immunicum to Present Data Update on Phase II ADVANCE II at Annual American Society of Hematology Meeting (ASH) Immunicum AB (publ; IMMU.ST), a biopharmaceutical company  focused on hard-to-treat established tumors and the prevention of cancer recurrence, announced today that updated results from the company’s ongoing ADVANCE II study with Immunicum’s cancer relapse vaccine DCP-001 will be presented at the 63rd American Society of Hematology (ASH) Annual Meeting to be held from December 11-14, 2021. The ADVANCE II study is an international, multi-center, open label Phase II study in which two different dosing regimens of DCP-001 are studied in acute myeloid leukemia patients with persistent measurable residual disease (MRD). “Initial results from the ADVANCE II study reported to date demonstrated that treatment...

EDIT-301 preclinical data support differentiated approach to develop a transformative medicine for people living with transfusion-dependent beta thalassemia Preclinical data demonstrating proprietary CRISPR/Cas12a multiplexed editing of iPSCs enhances iNK tumor killing ability, supporting promise as a potential therapeutic approach for solid tumors CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that two scientific abstracts have been accepted for presentation at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH), being held in Atlanta and virtually, December 11-14, 2021. The two abstracts outline preclinical data from the Company’s hemoglobinopathy and oncology programs. An additional oncology program abstract...

LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today provided a business update and reported financial results for the quarter ended September 30, 2021. “As we enter the last quarter of the year, we are approaching the conclusion of Part 1 of our Phase 2 clinical trial of KER-050 in patients with myelodysplastic syndromes (“MDS”). In preparation for Part 2 of this trial, we are excited to bring on additional clinical sites to increase patient recruitment, and look forward to providing a clinical data update at the 63rd American Society...

HOUSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming poster presentation at the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from December 11-14, 2021 in Atlanta, GA. In addition, ASH abstracts will appear in the November supplemental issue of Blood. Dr. Maro Ohanian, Associate Professor of the Department of Leukemia at The University of Texas M.D. Anderson Cancer Center, will present the safety and preliminary efficacy data from the ongoing Phase 2 trial of prexigebersen (BP1001), the Company’s lead drug candidate, for the treatment of acute myeloid leukemia.   Details...

LAFAYETTE, La., Nov. 04, 2021 (GLOBE NEWSWIRE) — Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD and TSX: VMD.TO), a home medical equipment supplier and the nation’s largest independent provider of ventilation that provides post-acute respiratory care services, announced today that Casey Hoyt, Chief Executive Officer, and Todd Zehnder, Chief Operating Officer will meet virtually with investors and present at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021 at 9:20 A.M. ET. WEBCAST LINK:   https://wsw.com/webcast/stifel58/vmd.to/2371680 Following the event, a replay of the presentation will be accessible through the Investor Relations section of the Company’s website at www.viemed.com. ABOUT VIEMED HEALTHCARE, INC. Viemed is a provider of in-home medical equipment and post-acute respiratory...

• Label highlights flavor, functional ingredients, and zero sugar, the main drivers of growth in the $7 billion performance drink market • Dual-language English and Spanish label$SBEV – Splash Beverage Group’s TapouT Performance Drink Gets Rebrand$SBEV – Updated TapouT BrandingFort Lauderdale, Florida, Nov. 04, 2021 (GLOBE NEWSWIRE) — Splash Beverage Group, Inc. (NYSE American: SBEV) (“Splash” or the “Company”), a portfolio company of leading beverage brands, today announced a rebranding of its TapouT performance hydration-recovery drink to launch January 2022. As the $7 billion performance drink market continues to gain momentum, the rebrand is intended to broaden consumer market appeal and help secure large distribution networks for TapouT into expanded retail and shelf space....

BELTSVILLE, Md., Nov. 04, 2021 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that new data from two research studies will be presented during oral and poster sessions at the 63rd annual American Society of Hematology (ASH) annual meeting, to be held in Atlanta, Georgia and in a virtual platform on December 11-14, 2021. The data come from research studies evaluating the role of Siglec-15 (S15) in B cell acute lymphoblastic leukemia (B-ALL) and potential to target S15 in childhood leukemia in collaboration with Emory University, and the impact of LAIR-1 expression on acute myeloid leukemia (AML) blasts and the use of LAIR-1 monoclonal antibodies...

TEJON RANCH, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) — Tejon Ranch Co., or the Company, (NYSE:TRC), a diversified real estate development and agribusiness company, today announced financial results for the three- and nine-months ended September 30, 2021. The Company operates in a variety of land-based business segments, including farming, mineral resources, and ranch operations, as well as a commercial/industrial mixed use master plan known as the Tejon Ranch Commerce Center, that is currently in operation focusing on leasing, development, and sales. The Company is also in the process of developing three additional mixed use master planned residential developments in southern California. When all four master planned developments are fully built out, Tejon Ranch will be home to 35,278 housing units, more than 35 million square feet...

Knock out of CD123 or CLL-1 by CRISPR-Cas9 from Human Hematopoietic Stem Cells Maintains Hematopoietic Function and is Resistant to Targeted Therapies Multiplex Engineering of Human CD34+ HSPCs Enables Dual Gene Knock-out with High Engraftment Potential Dual-Mobilized Donor Derived CD33 CAR T-Cells as Potent and Effective AML Therapy in Preclinical ModelsCAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) — Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the upcoming presentation of new data from its novel engineered hematopoietic stem cell (eHSC) platform at the American Society of Hematology (ASH) 63rd Annual Meeting, taking place in Atlanta, Georgia from December 11-14, 2021. “The data being presented at ASH underscore the potential of our novel cell and genome engineering platform...